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Abstract
Aims. To characterise purinergic signalling in overactive bladder (OAB).
Methods. Mucosal biopsies were taken by flexible cystoscopy from patients with storage 
symptoms referred to Urology Departments of collaborating hospitals. 
Immunohistochemistry (n=12) and western blotting (n=28) were used to establish the 
qualitative and quantitative expression profile of P2Y6 in human mucosa. Participants from 
the general population provided a mid-stream urine sample. Bioluminescent assays were 
used to quantify ATP (n=66) and ADP (n=60) concentrations, which were normalised to 
creatinine (Cr) concentration. All participants completed a questionnaire (ICIQ-OAB) to score 
urinary symptoms of OAB.
Results. P2Y6 immunoreactivity, more prominent in the urothelium (co-localised with the 
uroepithelial marker pan-cytokeratin), was more greatly expressed in OAB compared to age- 
and gender-matched controls (BPH) without OAB symptoms. Mucosal P2Y6 was positively 
correlated only with incontinence (p=0.009). Both urinary ATP and its hydrolysis product, ADP, 
an agonist to P2Y6, were positively correlated with total OAB symptom score (p=0.010 and 
p=0.042, respectively).
Conclusions. The positive correlation of P2Y6 only with incontinence may indicate a different 
phenotype in OAB wet and warrants further investigation. Positive correlations of ATP and 
ADP with total OAB symptom score demonstrate upregulation in purinergic signalling in OAB; 
shown previously only in animal models. Further research is required to validate whether 
purinoceptors are indeed new therapeutic targets for this highly prevalent symptom complex. 
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Introduction
Overactive bladder (OAB) is a symptom complex characterised by bothersome symptoms of 
urinary urgency, increased frequency, nocturia, with or without urge incontinence; in the 
absence of proven infection or other obvious pathology [1]. Despite being a highly prevalent 
condition, present in 9% to 43% of females and 7% to 27% of males [2], the underlying 
mechanisms of idiopathic OAB are not fully understood. Given that symptoms are associated 
with urine storage, research has focussed on mechanisms underlying the perception of 
bladder fullness. Distension of the urothelium during filling elicits non-neuronal release of 
ATP [3] which activates P2X3 and P2X2/3 purinoceptors on sub-urothelial nerve afferents [4]. 
Upregulation of ATP release has been demonstrated in in vitro preparations from patients 
with idiopathic OAB with detrusor overactivity (DO) [5] and manifests in increased urinary 
ATP concentration [6].
Release of ATP is itself likely to be modulated by P2Y purinoceptors; although the 
majority of the evidence for this comes from animal studies. P2Y agonists evoke ATP release 
[7], increase spontaneous contractions of the detrusor [8] and increase the frequency of 
voiding [9], to the point of evoking DO [10]. Underpinning these studies is the observation of 
P2Y-receptor mediated ATP release, suggesting an autocrine and / or paracrine feedback 
mechanism to enhance further release of ATP from the urothelium [7]; therefore, changes in 
the expression of P2Y receptors and / or molecules involved in its signalling pathway may 
amplify the bladder’s sensory responses seen in bladder conditions such as OAB. P2Y6 is 
expressed in the human bladder mucosa and its involvement in release of ATP from the 
urothelium has been demonstrated [11][12]. Therefore, any changes in P2Y6 expression may 
contribute to the symptoms of OAB.
The aim of this study was to characterise purinergic signalling in OAB; focussing on 
expression patterns of P2Y6 receptors in human mucosa layer, and investigating the 
associations of P2Y6 receptor expression and urothelial-derived signalling mediator, ATP and 
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Subjects and Methods
Participant recruitment and methods performed on data and samples are together 
summarised in Figure 1.
Human tissue and data collection
Participants for P2Y6 quantification analysis
Between 2010 and 2012, thirty-two participants were recruited from patients with storage 
symptoms referred to a specialist Urology Department at the Royal Surrey County Hospital, 
UK, for cystoscopic assessment. It is routine practise in the UK for small biopsies of mucosa to 
be taken by a flexible cystoscope for histological assessment. Ethical approval was given (REC: 
10/H1109/60) for an additional biopsy of mucosa to be taken by flexible cystoscope for the 
purposes of this study. Participants completed the ICIQ-OAB questionnaire to record their 
urinary symptoms and associated bother. Of the 32 participants, four biopsy samples were 
used for method optimisation and the remaining samples (n=28) were used for P2Y6 
quantification via Western blotting.
Participants for mucosal P2Y6 expression pattern analysis
Between 2015 and 2016, fourteen participants were recruited from patients with storage 
symptoms referred to a specialist Urology Department at the Shohada-e-Tajrish Hospital, 
Iran, for cystoscopic assessment. All participants completed a questionnaire (ICIQ-OAB) to 
score urinary symptoms of OAB. As in the UK, histological assessment of a small mucosal 
biopsy is routine and ethical approval was given (REC: 13/SC/0501) for an additional mucosal 
biopsy to be taken. During clinical examination, ten participants were diagnosed as having 
OAB and two were diagnosed as having benign prostatic hyperplasia and two participants 
were excluded due to missing clinical information. The P2Y6 expression of the mucosal 
biopsies from those twelve participants were characterised by immunohistochemistry.
Participants for urinary ATP and ADP concentration analyses
One hundred and thirteen volunteer participants were recruited (2014-2016, REC: 






























































washed three times in PBS for 10 minutes at room temperature (RT), then stored in PBS with 
0.02% sodium azide (sc-296028, Santa Cruz biotechnology, US) at 4°C and transferred to the 
University of Portsmouth (UK) for further processing and analysis. Biopsy samples were 
incubated in 30% sucrose solution overnight at 4°C, then embedded in OCT mounting medium 
(361603E, VWR, UK) and frozen. Cryosections (10 μm; 2-3 per slide) were mounted on 
Superfrost Plus™ microscope slides (J1800AMNZ, ThermoFisher Scientific, UK) and stored at 
−20°C until use. Cryosections were incubated with a blocking solution (2.5% normal horse 
serum; S-2012, Vector laboratories, UK) for 1 h at RT followed by incubation in mixture of 
primary antibodies, rabbit Anti-P2Y6 antibody (ab92504, 1:100, Abcam, UK) and mouse anti-
pan cytokeratin antibody (ab86734, 1:166, Abcam, UK) diluted in Tris-buffered saline 
containing 0.3% Triton-X100 (TBS-Tx) at RT for 2 h. Sections were then washed three times in 
TBS-Tx and incubated in a mixture of appropriate secondary antibodies conjugated with Alexa 
Page 5 of 38
Consented participants were asked to complete the ICIQ-OAB questionnaire and to provide a 
fresh midstream urine sample. Microscopic examination, dipstick urinalysis and chromogenic 
urinary tract infection medium test were immediately performed on a small proportion of 
each collected urine sample. According to the performed tests, 10 participants were 
diagnosed as having with yeast / bacterial infection or haematuria and four withdrew consent 
without reason, and therefore these participants were excluded from the study. The 
remaining urine samples (n=95) were utilised for ATP and ADP analyses. 
Inclusion Criteria: Male or female participants aged ≥18 and able to give informed consent 
for participation in the study. 
Exclusion Criteria: Male or female participants aged ≤18; taking any medication for OAB; 
unable to give informed consent; diagnosed with neurologic disease (stroke, MS, Parkinson’s 
disease, spinal cord injury); have a history of uterine, cervical, vaginal or urethral cancer; 
history of cyclophosphamide use or any type of chemical cystitis; history of benign or 
malignant bladder tumours; have had Botulinum toxin injections into the bladder, 
neuromodulation or augmentation cystoplasty.
Mucosal P2Y6 expression analysis
Bladder biopsies were immediately washed in PBS and fixed with 4% paraformaldehyde in 






























































Fluor 647 (donkey anti-rabbit IgG, 711-605-152, Jackson ImmunoResearch Laboratories, US) 
and Alexa Fluor 555 (goat anti-mouse IgG, ab150118, Abcam, UK) for 1 h at RT. The sections 
were then washed three times with TBS-Tx for 10 min, air dried and mounted with 
Vectashield® mounting medium with DAPI (H-1200, Vector Laboratories, UK). Slides were 
viewed at ×40 magnification using a confocal laser-scanning microscope (LSM710, Zeiss, 
Germany). Images were acquired using ZEN 9000 software and analysed by Image-J software. 
Presented immunofluorescence staining figures are representative images. A whole blot is 
shown in Supplementary Figure 1.
P2Y6 quantification analysis
Biopsies were immediately immersed in either Krebs physiological solution (120mM sodium 
chloride (NaCl), 15.5mM sodium hydrogen carbonate (NaHCO3), 2.5mM magnesium sulfate 
heptahydrate (MgSO4.7H2O), 5.9mM potassium chloride (KCl), 1.2mM potassium dihydrogen 
orthophosphate (KH2PO4)) and were transferred to the University of Portsmouth. Samples 
were immediately snap-frozen in liquid nitrogen and were lysed in radioimmunoprecipitation 
assay buffer containing a protease inhibitor (RIPA; Pierce 89900, Thermo Scientific, UK) using a 
mortar and pestle and were stored at -80 oC freezer until use. Protein concentrations of lysate 
samples were determined using bicinchoninic acid protein assay kit (Pierce 23227, 
ThermoFisher Scientific, UK), according to the manufacturer’s instructions. Ten micrograms of 
protein from each sample was separated using 10% SDS-PAGE and were wet transferred onto 
polyvinylidene difluoride membranes (overnight, 4°C). Membranes were then blocked with 5% 
milk-phosphate buffered saline (milk-PBS) for 1 h at RT. The membranes were then incubated 
with the mixture of primary antibodies, rabbit anti-P2Y6 antibody (ab92504, 1:1000, Abcam, 
UK) and anti-beta Actin (β-actin) antibody (ab8227, 1:1000, Abcam, UK) diluted into 3% milk-
PBS for 2 h, following which they were washed three times for 10 minutes in PBS-Tween 
(0.1%). Membranes were then incubated in an appropriate mixture of secondary antibodies 
conjugated with horseradish peroxidase including Goat Anti-Rabbit IgG (170-6515, Bio-Rad, 
UK) and Goat Anti-Mouse IgG (170-6516, Bio-Rad, UK) diluted in 5% Milk-PBS for 1 hr. The 
membranes were then washed three times for 10 minutes in PBS-Tween (0.1%). Immuno-
reactive bands were detected via an enhanced chemiluminescence reagent (Clarity™, 
1705061, Bio-Rad, UK / Luminata Forte, WBLUF0100, Merck Millipore, UK) and 
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were viewed using a Syngene / Bio-Rad chemiluminescent camera. The densities of the 
immunoreactive bands on the western blot images were quantified using ImageJ software 
and were standardised to their relative β-actin (i.e. P2Y6/β-actin) expression levels. The 
included western blot figure in this study is a representative blot. The researchers were 
blinded to participants’ ICIQ-OAB questionnaire information whilst running tests on the 
biopsy samples. Any participant who failed to complete part of the ICIQ-OAB questionnaire 
was excluded from the corresponding correlation analysis.
Urinary ATP and ADP concentration analyses
Microscopic examination, dipstick urinalysis and urine culture with chromogenic urinary tract 
infection test (PO0794A, Thermo Scientific, UK) were immediately performed on a small 
proportion of each collected urine sample. Details of the participants that this excluded are 
shown in Figure 1. The remainder of each eligible participant’s urine sample was centrifuged 
(at 4000 rpm, 10 mins, at 4°C), separated into cell pellet and supernatant and stored at -80°C 
until use. The urinary (cell-free) concentrations of ATP and ADP were measured in duplicate 
using ENLITEN® ATP assay system bioluminescence detection kit (FF2000, Promega, UK) and 
ADP assay kit (MAK133, Sigma-Aldrich, UK), respectively. The researchers were blinded to 
participants’ ICIQ-OAB questionnaire information whilst running tests on the urine samples. 
Any participant who failed to complete part of the ICIQ-OAB questionnaire or with a urinary 
ATP or ADP value outside the detection limit (standard curve) of the assays, was excluded 
from the corresponding correlation analysis.
Data and Statistical Analysis
D'Agostino-Pearson normality test was performed on all the generated data. Pearson 
product-moment correlation coefficient (parametric) or Spearman's rank correlation 
coefficient (non-parametric) were used for correlation analyses on untransformed data. 
GraphPad Prism 8.0.0 software was used for all the analyses and the preparation of lin-log 































































Immunolocalisation of P2Y6 receptors in human bladder mucosa biopsies
The presence of P2Y6 receptors in human bladder mucosa biopsies (n=12) was confirmed by 
immunofluorescence confocal microscopy. P2Y6 labelling was observed in both layers of 
human mucosa, i.e. urothelium and sub-urothelium layers (Figure 2). Analysis focussed on 
P2Y6 expression in mucosa at the two extremes of the ICIQ-OAB scores: a male participant 
diagnosed with OAB (ICIQ-OAB score: 13) and an age-matched male control with BPH (ICIQ-OAB 
score: 2) (Figure 2). The immunoreactivity for P2Y6 was more prominent in the 
urothelium layer of the OAB biopsy (Figure 2B) compared to the control biopsy (Figure 2A), 
where higher co-localisations of P2Y6 receptors with urothelial cells were observed in the 
OAB biopsy sample (Figure 2B; yellow in the merged images). 
Correlations between the expression levels of P2Y6 receptors in human bladder 
mucosa biopsy samples and OAB-associated clinical characteristics
The expression levels of P2Y6 receptors were studied in 28 human bladder mucosa biopsy 
samples and were correlated with participants’ OAB-associated clinical characteristics 
measured using the ICIQ-OAB questionnaire. These characteristics included individual and total 
OAB symptom scores and age. Specific immunoreactivity for P2Y6 protein in human mucosa 
samples was observed at the expected molecular weight of 42 KDa (Figure 3Ai). P2Y6 
expression, normalised to β-actin (i.e. P2Y6/β-actin), positively correlated with incontinence 
severity (Table 2). Expression did not correlate with total ICIQ-OAB symptom score (Figure 3Aii), 
nor frequency, nocturia, urgency scores or age (Table 2).
Correlations of the urinary levels of ATP and ADP with OAB-associated clinical 
characteristics
The urinary concentrations of ATP and its hydrolysis product, ADP, were measured in 95 
human urine samples. Measured urinary ATP and ADP levels were standardised to their 
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corresponding urinary creatinine concentrations (ATP/Cr; ADP/Cr) and their relationships 
with participants’ OAB-associated clinical characteristics and age were investigated (Figure 
3B,C).
Significant positive correlations were observed between the urinary levels of [ATP]/[Cr] and 
the total ICIQ-OAB symptom score (Figure 2B) and the frequency score (Table 2). Urinary 
[ATP]/[Cr] did not correlate with nocturia, urgency, incontinence scores or age (Table 2).
A significant positive correlation was observed between the urinary levels of [ADP]/[Cr] and 
the total ICIQ-OAB symptom score (Figure 2C). Urinary [ADP]/[Cr] did not correlate with 






























































Page 10 of 38
Discussion
The lack of understanding of the pathophysiological mechanisms underlying the development 
of OAB and its phenotypes has led to misdiagnosis, underdiagnosis and delayed treatment. 
Better symptom specific characterisation may help to better identify phenotypes and 
eventually lead to better treatment selection. Therefore, the aim of this study was to 
characterise the relationship between purinergic signalling and a spectrum of OAB-associated 
clinical characteristics.
We investigated the expression of P2Y6 purinoceptors in the mucosa layer of the human 
bladder, given compelling evidence from animal studies of modulation of non-neuronal ATP 
release by P2Y6 [9][10]. P2Y6 immunofluorescence was observed in urothelial and sub-
urothelial layers of human mucosa (Figure 2). Its expression was elevated in the mucosa of 
OAB patients compared to control patients (BPH) not exhibiting OAB symptoms; with a 
previous study having shown that urothelial P2Y6 is unaltered in BPH compared to controls 
[12]. The qualitative difference in expression with OAB is illustrated in Figure 2, which 
compares expression in an OAB patient (ICIQ-OAB score of 13) versus an age-matched 
asymptomatic (ICIQ-OAB score of 2) control.
To further investigate this observation and the idea that P2Y6 may be a therapeutic target for 
OAB, P2Y6 expression was quantified and correlated with total OAB symptom severity and 
the severity of individual symptoms, given a number of symptom combinations (OAB 
phenotypes) observed clinically [13]. A significant positive correlation was observed between 
the mucosal expression levels of P2Y6, normalised to β-actin (i.e. P2Y6/β-actin), and the 
severity of incontinence (Table 2). There was, however, no correlation between P2Y6/β-actin 
and the total ICIQ-OAB symptom score (Figure 3Aii), nor frequency, nocturia, urgency scores 
or age (Table 2). 
A positive correlation between P2Y6/β-actin and, of all symptoms, only incontinence requires 
interpretation. As recruitment of participants did not include urodynamics, we therefore 
cannot definitely rule out a contribution of SUI; however, given that the majority of 
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insignificant. Rather, as many OAB patients do not initially present with incontinence (‘OAB 
dry’), this symptom may, itself, may be seen as further development of the symptom complex 
[14] and thus P2Y6 expression a phenotype of this development; or ‘OAB wet’ is in itself an OAB 
phenotype, with a different pathophysiological basis that includes altered P2Y6 
expression. Future studies should further investigate the relationship between P2Y6 
expression in OAB-dry and OAB-wet, and with larger participant numbers.
Previous studies have shown that the activation of P2Y6 receptors modulates bladder 
urodynamics in anaesthetized rats; increasing voiding frequency [9] and inducing detrusor 
overactivity [10]. These effects were associated with an increase in urothelial ATP release, 
prompting our investigation into OAB symptom-associated changes associated with urinary 
ATP. For this, we chose to recruit from the general population, in order to give a broader 
spectrum of OAB symptom severity. ATP concentration, normalised to creatinine (i.e. 
[ATP]/[Cr]), was positively correlated with frequency and total symptom severity (Figure 2B, 
Table 2). While others have shown elevated [ATP]/[Cr] with DO [6] and elevated stretch-
evoked ATP release from the mucosa of DO patients [5], our study is the first to our knowledge 
to treat OAB symptom severity as a continuum. Participants in our study had, on average, 
relatively lower OAB symptom score severity (Table 1) compared to previous studies, 
however, the observation of significant correlations with the total ICIQ-OAB symptom scores 
suggests that ATP is elevated even with mild OAB; an observation that adds weight to the 
argument that it could be useful diagnostic biomarker. However, studies have shown that ATP is 
elevated in pyuria [15]; interstitial cystitis [16]; and BPH [17], so a lack of specificity may limit 
its usefulness. Future studies may want to include additional measures (such as more detailed 
questionnaires of urinary symptoms) to be certain of excluding these groups when recruiting 
from the general population.
In addition to the issue of whether ATP is specific to OAB is the observation that ATP is 
hydrolysed into ADP through ectonucleoside triphosphate diphosphohydrolases (E-
NTPDases) present in the mucosa layer. Little is known about the role and expression levels of 
these ectoenzymes in the human bladder in health and disease. Carneiro et al. 2014 
reported that dephosphorylation of ATP in rat predominantly occurs in the urothelium layer 
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more suitable indicator of OAB progression than ATP. ADP is, in itself, a ligand for P2Y6 [18] and 
we have shown its effects in an animal model of neurogenic OAB [8]. Therefore, the urinary 
levels of ADP and its association with OAB symptom severity was also investigated. Similar to 
ATP, a significant positive correlation was observed between the urinary levels of [ADP]/[Cr] and 
the total ICIQ-OAB symptom score (Figure 2C). Urinary [ADP]/[Cr] did not correlate with 
individual symptoms or age (Table 2).
Limitations
Samples from the same participants would allow multivariate analysis, but due to the sequential 
nature of this study, this was not possible; perhaps explaining the disparity in correlations 
between P2Y6/β-actin; [ATP]/[Cr]; [ADP]/[Cr] and expression with OAB-associated clinical 
characteristics.
In order to more fully address the hypothesis that OAB is characterised by an upregulation in 
purinergic signalling, the study would have benefitted from additional purines to ADP which act 
on P2Y6; specifically, UDP, 5-bromo-UPT and UTP [18]. Limitation in the methods used to 
measure these chemicals need to be overcome in order to allow a more complete study. The 
lack of urodynamic characterisation of recruited participants, such as to identify stress or mixed 
urinary incontinence, is a limitation of our study. It is not routine practise in the UK to perform 
urodynamics for uncomplicated storage symptoms and this is reflected in guidelines, such as the 
AUA/SUFU ‘diagnosis and treatment of overactive bladder (non-neurogenic) in adults. 
The collection sites for the different experimental tests did not control for the age and gender of 
the subjects which vary significantly across the sites. Future studies should address this 
shortcoming.
We cannot rule out the possibility that OAB was secondary to outflow obstruction. Future 
studies should therefore either involve participants with broad range of OAB symptoms in 
order to allow the identification of further OAB phenotypes, and should be extended to 
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The positive correlation of P2Y6 only with incontinence may indicate a different phenotype in 
OAB wet and warrants further investigation. Positive correlations of ATP and ADP with total 
OAB symptom score demonstrate upregulation in purinergic signalling in OAB; shown 
previously only in animal models. Further research is required to validate whether 
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RT: Room temperature 
TBS-Tx: Tris-buffered saline containing 0.3% Triton-X100
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Data Availability
The data that were generated and / or analysed for this study are available from the 
corresponding author upon request.
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Figure Legends
Figure 1. Flow diagram of participants recruitment, selection and subsequent tests. 
OAB: overactive bladder; BPH: benign prostatic hyperplasia; ICIQ-OAB = 
International consultation on incontinence questionnaire - overactive bladder; a = see 
Methods and Materials section for inclusion and exclusion criteria.
Figure 2. Representative images of immunolocalisation of P2Y6 receptors in human 
bladder mucosa biopsies from control (BPH) and OAB individuals. 
Cryosections (10µm) of human bladder biopsies were labelled with antibodies to 
P2Y6 (green); urothelium layer is labelled with pan-cytokeratin antibodies (red); nuclei are 
labelled with DAPI (blue). White arrow: denotes co-localisation (yellow in the merged 
images) of P2Y6 receptors with urothelial cells; images were acquired using 
confocal microscopy, magnification: 40X, scale bar=20µm; BPH: benign prostatic 
hyperplasia; OAB: overactive bladder.
Figure 3. Associations of mucosal P2Y6 receptor expression and urinary ATP and ADP with 
total ICIQ-OAB score. (A) i. Representative Western blots of P2Y6 (42 KDa, expected band 
size) and β-actin (47 KDa, expected band size) expressions in human bladder mucosa 
biopsy samples; + control: human bronchial epithelium lysate; - control: human bronchial 
epithelium lysate with no P2Y6 primary antibody. ii. Correlation between the expression 
levels of P2Y6 (normalised to β-actin) and participants’ total ICIQ-OAB severity scores, 
shown on a linear graph. (B) Correlation between the urinary levels of ATP normalised to 
creatinine (ATP/Cr) and participants’ total ICIQ-OAB severity scores, shown on a lin-log 
plot. (C) Correlation between the urinary levels of ADP normalised to creatinine (ADP/Cr) 
and participants’ total ICIQ-OAB severity scores, shown on a lin-log plot. p: p-value; r: 





























































Table 1. Characteristics of study participants used for analyses. 










n 10a 28 66 60
Age, mean (range) (yrs) 61 (46-82) 69 (37-92) 52 (21-93) 54 (21-93)
Gender
     Female 7 10 49 36
     Male 3 18 17 24
ICIQ-OAB characteristics
Frequencyb, mean (SD) 0.77 (±0.42) 0.52 (±0.33) 0.37 (±0.31) 0.36 (±0.32)
Nocturiab, mean (SD) 0.73 (±0.34) 0.56 (±0.27) 0.15 (±0.18) 0.17 (±0.19)
Urgencyb, mean (SD) 0.75 (±0.31) 0.36 (±0.23) 0.17 (±0.18) 0.20 (±0.20)
Incontinenceb, mean (SD) 0.74 (±0.31) 0.18 (±0.20) 0.09 (±0.17) 0.10 (±0.18)
Total ICIQ-OAB symptom 
scoreb, mean (SD)
0.74 (±0.28) 0.39 (±0.16) 0.18 (±0.13) 0.19 (±0.14)
a Participants diagnosed as having OAB (for further information see Figure 1); b Symptoms scores were 
range standardised on a 0 to 1 scale.
Table 2. Correlations between mucosal P2Y6 receptor expression and urinary ATP and ADP 
concentrations with overactive bladder characteristic symptom severity and age. Urinary 
concentrations of ATP and ADP were normalised to urinary creatinine concentration. 
Significant correlations (i.e. p-value of 9 0.05) are highlighted in bold.






p-value 0.629 0.000 0.277Frequency severity score
r 0.096 0.460 0.143
p-value 0.134 0.996 0.384Nocturia severity score
r 0.291 0.001 0.115
p-value 0.864 0.157 0.165Urgency severity score
r 0.034 0.176 0.182
p-value 0.009 0.315 0.306Incontinence severity score
r 0.487 0.126 0.134
p-value 0.107 0.010 0.042Total ICIQ-OAB score
r 0.311 0.315 0.264
p-value 0.507 0.077 0.995Age
r 0.131 0.219 -0.001





























































Figure 1. Flow diagram of participants recruitment, selection and subsequent tests.
OAB: overactive bladder; BPH: benign prostatic hyperplasia; ICIQ-OAB = International consultation on 
incontinence questionnaire - overactive bladder; a = see Methods and Materials section for inclusion and 
exclusion criteria. 
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Figure 2. Representative images of immunolocalisation of P2Y6 receptors in human bladder mucosa biopsies 
from control (BPH) and OAB individuals. 
Cryosections (10µm) of human bladder biopsies were labelled with antibodies to P2Y6 (green); urothelium 
layer is labelled with pan-cytokeratin antibodies (red); nuclei are labelled with DAPI (blue). White arrow: 
denotes co-localisation (yellow in the merged images) of P2Y6 receptors with urothelial cells; images were 
acquired using confocal microscopy, magnification: 40X, scale bar=20µm; BPH: benign prostatic 
hyperplasia; OAB: overactive bladder. 
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Figure 3. Associations of mucosal P2Y6 receptor expression and urinary ATP and ADP with total ICIQ-OAB 
score. (A) i. Representative Western blots of P2Y6 (42 KDa, expected band size) and β-actin (47 KDa, 
expected band size) expressions in human bladder mucosa biopsy samples; + control: human bronchial 
epithelium lysate; - control: human bronchial epithelium lysate with no P2Y6 primary antibody. ii. 
Correlation between the expression levels of P2Y6 (normalised to β-actin) and participants’ total ICIQ-OAB 
severity scores, shown on a linear graph. (B) Correlation between the urinary levels of ATP normalised to 
creatinine (ATP/Cr) and participants’ total ICIQ-OAB severity scores, shown on a lin-log plot. (C) Correlation 
between the urinary levels of ADP normalised to creatinine (ADP/Cr) and participants’ total ICIQ-OAB 
severity scores, shown on a lin-log plot. p: p-value; r: Spearman / Pearson r value; Bold value: significant 
p-value of ≤ 0.05.
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P2Y6, Abcam 92504, expected band size : 42 KDa
β-actin, Abcam 8227, expected band size: 47 KDa
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